PresentationMaybe to start, just hand the floor to you for a few minutes, high-level overview, current state of affairs, where you are in the growth journey. Any highlights from the third quarter that you reported about a month ago? And we'll jump into questions from there.So just continuing on the third and final day of our Citi Global Healthcare Conference. I'm Traver Davis, health care sector specialist at Citi, and we're delighted to have Teva with us. From the company, we have Richard Francis, Presiden ...

Teva Pharmaceutical Industries Conference Summary Company Overview - **Company**: Teva Pharmaceutical Industries (NYSE: TEVA) - **Event**: Jefferies London Healthcare Conference - **Date**: November 18, 2025 Key Points Pivot to Growth Strategy - Teva is in a three-stage pivot to growth strategy: 1. **Return to Growth**: Achieved 11 consecutive quarters of growth 2. **Accelerate Growth**: Focus on innovative business to enhance growth 3. **Maintain Growth**: Currently in this phase with expectations for further advancements based on innovative products and pipeline [3][4][5] Financial Performance and Guidance - Innovative business sales reached over $800 million in Q3, growing by 33% [4] - Key products driving growth include: - **Austedo**: 38% growth - **Uzedy**: 24% growth - **Ajovy**: 19% growth [5] - Anticipated loss of $1 billion in revenue from generic Revlimid in 2026, but EBITDA is expected to grow due to innovative business growth and operational efficiency [9][10] - Organizational effectiveness plan aims to save $700 million by 2027, with two-thirds of savings expected by the end of 2026 [9][10] Innovative Portfolio Highlights - **Austedo**: - 2027 guidance of at least $2.5 billion in sales, with peak sales projected over $3 billion [11][12] - 85% of patients with tardive dyskinesia remain untreated, presenting a significant growth opportunity [15] - **Uzedy**: - Long-acting treatment for schizophrenia, forecasted to generate $200 million this year, with potential franchise sales of $1.5 billion to $2 billion [24][25] - **Olanzapine**: - Long-acting formulation expected to launch in late 2026, with potential for significant market impact [26][32] Pipeline and Future Catalysts - Teva has a robust late-stage pipeline with several upcoming data readouts and product launches: - **Duvakitug**: Targeting multiple indications, partnered with Sanofi for broader market reach [41][42] - **Anti-IL-15**: Expected data readouts in vitiligo and celiac disease [34] - **Emrysoma**: Treatment for MSA with futility analysis upcoming [34] - The company aims for a $5 billion-plus innovative portfolio by 2030 [33] Market Position and Competitive Landscape - Teva emphasizes a disciplined approach to balancing access and value in a competitive market [18][19] - The company is focused on maintaining operational excellence while expanding its innovative portfolio [22] Investor Sentiment - Current investor sentiment may not fully appreciate the value of Teva's pipeline and innovative products, with a call for better recognition of their potential [38][39] Conclusion Teva Pharmaceutical Industries is strategically positioned for growth through its innovative portfolio and operational efficiency. The company is focused on maintaining momentum in its growth trajectory while navigating challenges in the market, particularly with the anticipated loss of revenue from Revlimid. The upcoming product launches and pipeline developments are expected to significantly contribute to Teva's long-term success and shareholder value.

Teva Pharmaceutical Industries (TEVA) FY Conference Summary Company Overview - **Company**: Teva Pharmaceutical Industries (TEVA) - **Date of Conference**: June 10, 2025 - **Key Speaker**: Richard France, President and CEO Key Industry Insights - **Transition to Biopharma**: Teva is transitioning from a pure play generics company to a biopharma company, with a focus on innovative products and a robust pipeline [4][5] - **Acceleration Phase**: The company has entered an acceleration phase in its growth strategy, aiming to commercialize innovative products and expand its portfolio [2][3] Financial Performance - **Revenue Growth**: Teva has achieved consecutive growth, with Q1 marking a significant milestone. The company aims to generate over $1 billion in revenue from its innovative portfolio by 2027 [5][6] - **Generics Business**: The generics segment is expected to remain flat due to the loss of generic Revlimid, but Teva plans to stabilize and grow this segment through a deep pipeline of products [8][9][10] Product Pipeline and Market Dynamics - **Innovative Products**: Key products include AUSTEDO, YUCEDY, and AJOVY, with a focus on addressing significant unmet medical needs [5][6] - **AUSTEDO Growth**: AUSTEDO has shown strong growth, with long-term guidance projecting over $3 billion in sales by 2030, driven by a large untreated population [32][34] - **Long-Acting Treatments**: Teva is optimistic about the potential of long-acting treatments like olanzapine, with peak sales guidance of $1.5 billion to $2 billion [42][44] Cost Management and Capital Allocation - **Cost Reduction Initiatives**: Teva has implemented a $700 million cost reduction program to optimize capital allocation towards innovative products while compensating for losses from generics [12][13] - **Focus on Returns**: The company emphasizes a disciplined approach to capital allocation, prioritizing investments that yield high returns, particularly in the innovative segment [12][70] Regulatory and Macro Environment - **Pharma Tariffs**: Teva is preparing for various scenarios regarding potential pharma tariffs, indicating a proactive approach to managing risks [19][20] - **Engagement with Administration**: Teva actively engages with policymakers to advocate for the generics sector, highlighting its importance in the healthcare system [22][23] Future Outlook - **Pipeline Development**: Teva is focused on advancing its pipeline, including partnerships with companies like Sanofi to expedite the development of promising assets [61][62] - **Market Opportunities**: The company sees significant opportunities in the dual-action rescue inhaler market and other innovative treatments, with expectations of capturing a substantial market share [66][67] Conclusion Teva Pharmaceutical Industries is strategically positioned for growth through its transition to a biopharma company, a strong focus on innovative products, and disciplined capital allocation. The company is navigating challenges in the generics market while capitalizing on opportunities in its product pipeline, aiming for sustained revenue growth and improved profitability.

Summary of Curtiss Wright's Presentation at the William Blair Growth Stock Conference Company Overview - **Company**: Curtiss Wright - **Industry**: Aerospace and Defense - **Key Personnel**: CEO Lynn Bamford, CFO Chris Farkas, Head of Investor Relations Jim Ryan - **Milestone**: Celebrated 95 years on the New York Stock Exchange [8][9] Core Messages - **Pivot to Growth Strategy**: Launched four years ago, focusing on growth and operational excellence [6][12] - **Financial Performance**: Strong financial results with a track record of achieving financial targets set during Investor Days [7][12] - **Engineering Workforce**: Approximately 9,000 employees, with 2,000 engineers, emphasizing collaboration and talent development [11] Operational Strategies - **Operational Growth Platform**: Focus on maximizing profitability through commercial and operational excellence [12] - **R&D Investments**: Increased R&D investments above sales growth, contributing to margin expansion and earnings growth in the mid-teens [12][26] - **Cost Efficiency**: Ongoing consolidation programs to drive efficiencies and reinvest in the business [13] End Markets and Growth Opportunities - **Navy Footprint**: Significant supplier for U.S. Navy platforms, targeting increased content for future generation platforms [19][20] - **Defense Electronics**: Partnership with NVIDIA to enhance electronics capabilities for battlefield technology [20] - **Nuclear Industry**: Focus on aftermarket services, life extensions, and new reactor builds, including small modular reactors (SMRs) [18][22][24] Market Trends - **Commercial Aerospace**: Anticipated multiyear ramp in growth, heavily focused on OEM [31] - **Foreign Military Spending**: Increased spending contributing to growth in defense markets [31] - **Nuclear Energy Expansion**: Targeting significant growth in nuclear energy, with potential for $1.5 billion in market share from Eastern Europe and additional opportunities from U.S. reactor builds [28][39][40] Financial Targets and Performance - **Sales Growth**: Targeting over 5% organic sales growth, with mid to high single-digit growth in defense markets [31] - **Operating Margins**: Expected operating margin expansion, with a current target of 18.4% [34] - **Free Cash Flow**: Projecting $1.3 billion in free cash flow over three years, with a strong focus on capital allocation [35][36] Future Outlook - **Nuclear Reactor Opportunities**: Anticipating orders for AP1000 reactors in 2026, with significant growth potential in the nuclear sector [43] - **Strategic Partnerships**: Collaborations with major players in the nuclear industry to enhance market position [40][41] Conclusion - **Investment Proposition**: Curtiss Wright's pivot to growth strategy is yielding positive results, with strong market positioning and a focus on delivering value to shareholders [28][29]